---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-249692"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2026-06-01T11:00:19+00:00"
generated_at: "2026-06-01T11:06:39.408014+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors

## Summary
- Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
- Stockholders holding 57.1% of shares approved via written consent on April 28, 2026.
- Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (Canaan Partners GP) to Board.
- Board reduced from six to five directors; each new director received an option to purchase 13,587 shares.
- Common stock trading on OTC Pink under symbol ELOX will begin split-adjusted on June 1, 2026.

## SEC filing metadata
- accession: 0001193125-26-249692
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2026-06-01T11:00:19+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.02, 3.03, 5.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-249692
- JSON: https://secwatch.observer/filing/0001193125-26-249692.json
- Plain text: https://secwatch.observer/filing/0001193125-26-249692.txt

## Source-grounded claims
- claim_id: 14d4f6818a
  claim: Stephen W. Webster was appointed as Director at Eloxx Pharmaceuticals, Inc..
  evidence_excerpt: the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm
- claim_id: b89010160f
  claim: Nina Kjellson was appointed as Director at Eloxx Pharmaceuticals, Inc..
  evidence_excerpt: the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.